[Aspirin, oral anticoagulants, and heart failure].
The incidence of thromboembolic complications in patients with cardiac failure is low. The predisposing factors are principally the presence of a left ventricular mural thrombus, atrial fibrillation, a low ejection fraction and a low peak VO2. The risk of cerebral haemorrhage in a patient with cardiac failure treated with oral anticoagulants is about the same as the risk of thromboembolism. Therefore, anticoagulant therapy for patients with cardiac failure is controversial in the absence of a prospective large scale clinical trial demonstrating its benefits. In the meantime, a prudent approach with risk stratification to determine which patients would benefit the most from oral anticoagulation is advised.
Gibelin
P
P
Service de cardiologie, CHU Pasteur, Nice.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D000075202:Contraindications; D006333:Heart Failure / Q000150:complications*; D006801:Humans; D012307:Risk Factors; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*
D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D001241:Aspirin
Aspirine, antivitamines K et insuffisance cardiaque chronique.